Acinetobacter baumannii complex: Difference between revisions
From IDWiki
Acinetobacter baumannii complex
Content deleted Content added
m Text replacement - "[[Has Gram stain::" to "[[Stain::" |
No edit summary |
||
| Line 1: | Line 1: | ||
== Background == |
|||
| ⚫ | |||
| ⚫ | |||
=== Microbiology === |
|||
| ⚫ | |||
| ⚫ | |||
== Management == |
|||
* Choice of antibiotic depends on susceptibility testing |
|||
* Possible options include: |
|||
** [[Cefepime]], [[ceftriaxone]], and [[cefotaxime]] |
|||
** [[Cefiderocol]] |
|||
** [[Carbapenems]] |
|||
** [[Tigecycline]] |
|||
** [[Colistin]] and [[polymyxin B]] (though [[Acinetobacter junii]] has inherent resistance) |
|||
* [[Aminoglycosides]] may not penetrate well into lungs and brain, so are usually avoided |
|||
* [[Bacteriophages]] are promising |
|||
{{DISPLAYTITLE:''Acinetobacter baumannii'' complex}} |
{{DISPLAYTITLE:''Acinetobacter baumannii'' complex}} |
||
[[Category:Gram-negative bacilli]] |
[[Category:Gram-negative bacilli]] |
||
Revision as of 22:48, 28 August 2020
Background
Microbiology
- Contains Acinetobacter baumannii, Acinetobacter nosocomialis, and Acinetobacter pittii
- Non-motile, non-fermenting Gram-negative bacillus
Management
- Choice of antibiotic depends on susceptibility testing
- Possible options include:
- Cefepime, ceftriaxone, and cefotaxime
- Cefiderocol
- Carbapenems
- Tigecycline
- Colistin and polymyxin B (though Acinetobacter junii has inherent resistance)
- Aminoglycosides may not penetrate well into lungs and brain, so are usually avoided
- Bacteriophages are promising
References
- ^ Mical Paul, Elena Carrara, Pilar Retamar, Thomas Tängdén, Roni Bitterman, Robert A. Bonomo, Jan de Waele, George L. Daikos, Murat Akova, Stephan Harbarth, Celine Pulcini, José Garnacho-Montero, Katja Seme, Mario Tumbarello, Paul Christoffer Lindemann, Sumanth Gandra, Yunsong Yu, Matteo Bassetti, Johan W. Mouton, Evelina Tacconelli, Jesús Rodríguez-Baño. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection. 2022;28(4):521-547. doi:10.1016/j.cmi.2021.11.025.
